From the Team That Helped Write the Guidance.

Compliance intelligence from people
who’ve been in those audit rooms.

Our executives were key contributors to the FDA’s CSA guidance — FICSA co-founders. When we write about AI governance, inspection readiness, or CSA transformation, we’re drawing on 25 years of seeing what works and what doesn’t under FDA scrutiny — and 300+ GxP system validation packages refined through real inspections.

AI Gov

CLAiRE AI Agentic Platform & ISO/IEC 42001

CSA

Validation modernization

Data

Data integrity & CLAiRE ATR

QMSR

Regulatory intelligence

Content categories

Find what you’re looking for.

CLAiRE AI Agentic Platform & ISO/IEC 42001

What the FDA is actually asking in current inspections. ISO/IEC 42001 for life sciences. EU AI Act timelines. The six CLAiRE capabilities and how they reduce validation effort by up to 29%. Building defensible AI governance frameworks.

CSA / Validation Modernization

The difference between checkbox CSA and methodology change. Phase-by-phase efficiency gains with CLAiRE AI. How to reduce validation cycle time by 40–70%. Retrospective CSA remediation. iQuality VX in practice.

Data Integrity & CLAiRE ATR

Why quarterly sampling creates 90-day blind windows. What CLAiRE AI Agentic Platform 100% continuous ATR changes — 40% Review & Approval savings. ALCOA+ in the age of AI. Real program outcomes from Sarepta, Vericel, Regeneron, and peers.

Inspection Readiness & QMSR

QMSR is live — what it means for your quality system. Pre-inspection preparation that actually works. Zero major audit observations: what it takes to commit to that. EU GMP Annex 11 updates.

Featured posts

Latest from Compliance Group.

AI · July 2026

Continuous AI Validation in GxP Environments: A Risk-Based Approach for Life Sciences

Article Context: Computer System Validation AI Validation AI Validation Framework Agentic AI Platform Implementation of AI solutions is evolving quickly from experimentation to operational deployment within the life sciences industry....

Read Article
FDA · July 2026

FDA 483 Letters: Most Common Observations & Risks

Article Context: FDA Regulatory FDA Observations FDA Observations & Warning Letter Compliance Strategies An FDA inspection letter goes hand in hand with running a business that produces medical devices. It...

Read Article
AI · June 2026

Modern Compliance in Regulated Life Sciences: The Complete Guide to CSA, AI Governance, and Intelligent Quality Management

Frequently Asked Questions What is the difference between Computer Software Assurance (CSA) and Computer System Validation (CSV)? CSV is a documentation-driven approach to software validation that was designed in the...

Read Article
QMS · June 2026

You Have a QMS. You Still Only Review 3% of Your Audit Trail. Meet CLAiRE.

Article Context: Gaps in QMS QMS Records ClAiRE MAiGRATE AI agents that layer on top of the quality infrastructure you already have—no rip-and-replace required. Just intelligence where your current system...

Read Article

Compliance Group Insights Newsletter

Get regulatory intelligence in your inbox.

  • Bi-weekly
  • Practitioner-written
  • No spam
  • Unsubscribe anytime